As number of COVID-19 cases in Russia crossed 500,000, the government has rolled out a drug to treat the novel coronavirus even though clinical trials are still underway.
The country's health ministry has approved the use of the anti-viral drug, registered under the name Avifavir, under a special accelerated process.
In a press release, the state financial backer said the drug has been delivered to some hospitals and clinics in the country.
The country's RDIF sovereign wealth fund has a 50 per cent share in a joint venture with the drug's manufacturer ChemRar.
There is currently no vaccine for COVID-19, with human trials of several existing antiviral drugs yet to show efficacy.
So far, the country has 502,436 positive cases and the death toll stands at 6,532.


Determined to seize Greenland, Trump faces tough reception in Davos
South Korea court sentences ex-PM Han to 23-year jail term in martial law case
Japan court sentences ex-PM Shinzo Abe's assassin to life in prison
Commuter train derailment near Barcelona kills driver, injures 37
Arab Parliament condemns Israeli raid on UNRWA headquarters
